GenMark Diagnostics receives FDA clearance for BCID-GN Panel

GenMark诊断公司的ePlex血液培养鉴定革兰阴性组获FDA许可

2019-04-15 21:30:28 seekingalpha

本文共114个字,阅读需1分钟

标签: 生物技术
The FDA has granted FDA 510 market clearance to GenMark Diagnostics for its ePlex Blood Culture Identification Gram-Negative Panel. The ePlex BCID Panels provide broad coverage of organisms and resistance markers that can lead to sepsis, including anaerobes and multidrug resistant organisms, as well as common and emerging fungal pathogens.
FDA 已经授予 FDA 510市场许可 GenMark 诊断其 ePlex 血液培养鉴定革兰阴小组。 ePlex BCID 小组提供了广泛的生物和耐药标记,可导致败血症,包括厌氧菌和多重耐药微生物,以及常见和新兴的真菌病原体。